Integra LifeSciences Holdings Corporation cash flow to debt ratio of 2.48% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Integra LifeSciences Holdings Corporation's free cash flow has decreased 281.28% from $24.96M last year to $-45.25M, signaling decreasing performance

Integra LifeSciences Holdings Corporation's debt to equity ratio is 1.94, which means that the company's assets are unhealthy financed, signaling financial risk.

Integra LifeSciences Holdings Corporation's debt has increased relative to shareholder equity from 1.28 last year to 1.94 today, signaling weakened financials

Integra LifeSciences Holdings Corporation has negative EBITDA, making leverage ratio unreliable

Integra LifeSciences Holdings Corporation's interest coverage ratio of 6.82 indicates that earnings with good margin can cover interest payments on company debt

Integra LifeSciences Holdings Corporation's profit margin has decreased (1.96%) in the last year from -0.43% to -0.44%, signaling decreasing performance

Integra LifeSciences Holdings Corporation's short-term assets of $1.16B exceed its short-term liabilities of $455.98M

Integra LifeSciences Holdings Corporation's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Integra LifeSciences Holdings Corporation's return on equity of -0.69%, is lower than 15.00%, indicating bad performance

Integra LifeSciences Holdings Corporation's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Integra LifeSciences Holdings Corporation had positive net income in 3 out of 5 years, indicating stable and consistent earnings

Integra LifeSciences Holdings Corporation has negative free cash flow, indicating the company is burning cash rather than generating it

Integra LifeSciences Holdings Corporation has negative free cash flow, indicating cash burn

Integra LifeSciences Holdings Corporation's yearly earnings has decreased 7.34K% since last year from $-6.94M to $-516.47M, signaling decreasing performance

Integra LifeSciences Holdings Corporation's yearly revenue has increased 1.53% since last year from $1.61B to $1.64B, signaling increasing performance

ROIC 19.92% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

Integra LifeSciences Holdings Corporation's 3-year revenue CAGR of 1.63% is positive, indicating growing revenue over the past 3 years

Integra LifeSciences Holdings Corporation had revenue growth in 4 out of 5 years, indicating consistent revenue performance

Integra LifeSciences Holdings Corporation had positive ROE in 3 out of 5 years, indicating consistent and reliable returns on equity

Integra LifeSciences Holdings Corporation has insufficient data to evaluate this check.

Integra LifeSciences Holdings Corporation has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Integra LifeSciences Holdings Corporation is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Integra LifeSciences Holdings Corporation has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Integra LifeSciences Holdings Corporation is undervalued relative to its fair value price of 21.24 based on Earnings Fair Value model

Integra LifeSciences Holdings Corporation has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Integra LifeSciences Holdings Corporation has a price-to-book ratio of 1.27x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Integra LifeSciences Holdings Corporation has a price-to-sales ratio of 0.81x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue